Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 2Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Genitourinary 1Endocrine 1

Conditions

Carcinoma, Hepatocellular 121Carcinoma, Renal Cell 60Neoplasms 43Liver Neoplasms 42Neoplasm Metastasis 23Carcinoma, Non-Small-Cell Lung 21Leukemia, Myeloid, Acute 20Melanoma 18Kidney Neoplasms 16Breast Neoplasms 16Brain Neoplasms 13Pancreatic Neoplasms 12Sarcoma 11Prostatic Neoplasms 10Glioblastoma 10Lung Neoplasms 9Thyroid Neoplasms 8Recurrence 8Rectal Neoplasms 8Colorectal Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Colonic Neoplasms 7Stomach Neoplasms 6Ovarian Neoplasms 6Multiple Myeloma 6Leukemia 6Gliosarcoma 6Carcinoma 6Unspecified Adult Solid Tumor, Protocol Specific 5Urinary Bladder Neoplasms 4

Interventions

Magnetic Resonance Spectroscopy 4Iodine-131 4Sunitinib 3dabrafenib 2Trastuzumab 2Thyrotropin Alfa 2Thyroidectomy 2Surgical Procedures, Operative 2Gefitinib 2Fluorodeoxyglucose F18 2Bortezomib 2AZD 6244 22-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 2tumor necrosis factor-alpha, CNGRC fusion protein, human 1trametinib 1tipifarnib 1tanespimycin 1sargramostim 1romidepsin 1pralsetinib 1pembrolizumab 1pazopanib 1motesanib diphosphate 1mercaptoundecahydrododecaborate 1lenvatinib 1delta 24-sterol reductase 1copanlisib 1cediranib 1aldesleukin 1aflibercept 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Thyroid Cancer, Papillary × Sorafenib × Clear all
NCT01502410 2018-06-26

Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer

National Cancer Institute (NCI)

Phase 2 Completed
20 enrolled 14 charts
EndocrineGenitourinaryHead & Neck

Thyroid Cancer, Papillary, Wilms Tumor, Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡